Gene Therapies: Safety, CMC Draft Guidances Coming From US FDA In 2018
Executive Summary
Lengthy safety registries, extensive premarket testing for replication competent retrovirus, and manufacturing submission advice likely; pending CBER documents informed by review and approval of Novartis' Kymriah, Kite's Yescarta, and Spark's Luxturna.
You may also be interested in...
Reagan-Udall Annual Meeting: 4 Takeaways From US FDA Center Directors
US FDA's center directors chime in on topics such as antimicrobial drug development and public education at the 2019 Reagan-Udall annual meeting.
Gottlieb On Gene Therapies: 'Very Seductive' To Think About Accelerated Approval Pathway
Accelerated approval would help agency monitor gene therapies for durability and off-target effects, US FDA commissioner says.
Gene Therapy Manufacturing Remains Large Hurdle For Development, US FDA's CBER Director Says
Scale-up in particular is a challenge and FDA wants to help lower the barrier, CBER Director Peter Marks tells rare disease conference.